ArticleJournal of Alzheimer's disease : JAD2015
Inhalable curcumin: offering the potential for translation to imaging and treatment of Alzheimer's disease.
Article in Journal of Alzheimer's disease : JAD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 48 citations in OpenAlex.
- Translational Feasibility of Curcumin for Treatment of Alzheimer's Disease: A Critical Appraisal of Clinical Challenges.Antioxidants (Basel, Switzerland) · 2026Review
- Systematic review of curcumin-based optical imaging for amyloid-β detection in Alzheimer's disease models.Current journal of neurology · 2025Review
- Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease.ACS sensors · 2024Article
- A novel antioxidant ergothioneine PET radioligand for in vivo imaging applications.Scientific reports · 2021Article
- Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer's amyloidosis.Alzheimer's research & therapy · 2021Article
- Inhalable Thioflavin S for the Detection of Amyloid Beta Deposits in the Retina.Molecules (Basel, Switzerland) · 2021Article
- Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection.Molecules (Basel, Switzerland) · 2020Review
- Theracurmin Ameliorates Cognitive Dysfunctions in 5XFAD Mice by Improving Synaptic Function and Mitigating Oxidative Stress.Biomolecules & therapeutics · 2019Article
- Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease.Neural regeneration research · 2018Review
- Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer's disease.BMC neuroscience · 2018Article
- Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Review
- Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2017Article
- A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5×-familial Alzheimer's disease mice.Histochemistry and cell biology · 2016Article
- Novel curcumin derivatives as potent inhibitors of amyloid β aggregation.Biochemistry and biophysics reports · 2015Article
- Anti-dementia medications: current prescriptions in clinical practice and new agents in progress.Therapeutic advances in drug safety · 2015Review
- Effect of curcumin on aging retinal pigment epithelial cells.Drug design, development and therapy · 2015Article
- Curcumin-encapsulating Nanogels as an Effective Anticancer Formulation for Intracellular Uptake.Molecular and cellular pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Curcumin is a promising compound that can be used as a theranostic agent to aid research in Alzheimer's disease. Beyond its ability to bind to amyloid plaques, the compound can also cross the blood-brain barrier. Presently, curcumin can be applied only to animal models, as the formulation needed for iv injection renders it unfit for human use. Here, we describe a novel technique to aerosolize a curcumin derivative, FMeC1, and facilitate its safe delivery to the brain. Aside from the translational applicability of this approach, a study in the 5XFAD mouse model suggested that inhalation exposure to an aerosolized FMeC1 modestly improved the distribution of the compound in the brain. Additionally, immunohistochemistry data confirms that following aerosol delivery, FMeC1 binds amyloid plaques expressed in the hippocampal areas and cortex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.